Boston Scientific Corporation $BSX Shares Acquired by Leavell Investment Management Inc.

Leavell Investment Management Inc. lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 283.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 8,402 shares of the medical equipment provider’s stock after acquiring an additional 6,212 shares during the quarter. Leavell Investment Management Inc.’s holdings in Boston Scientific were worth $820,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Steph & Co. purchased a new position in shares of Boston Scientific during the third quarter worth $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific during the 3rd quarter worth about $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific during the 2nd quarter valued at about $26,000. Sound Income Strategies LLC grew its position in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in Boston Scientific during the second quarter worth about $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 93,095 shares of company stock valued at $9,305,450. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $88.13 on Monday. The stock’s 50-day simple moving average is $96.90 and its 200-day simple moving average is $100.27. The firm has a market capitalization of $130.65 billion, a PE ratio of 47.13, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the business posted $0.63 EPS. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on BSX shares. Robert W. Baird raised their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Wells Fargo & Company raised their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Citigroup restated a “buy” rating on shares of Boston Scientific in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $123.89.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.